Figure 5.

IL-33 Tregs are potently functional in vivo. A, Schematic of experimental skin transplant model design. CBA/Ca Rag1^-/- (H-2^k) received control CD4⁺GFP^neg effector T cells (Teff) with or without CD4⁺GFP⁺ Tregs from H-2^k Foxp3-GFP mice that were treated with PBS or IL-33 (1 μg/d for 6 consecutive days and sacrificed on day 7). One day later, mice received an allogeneic fully MHC mismatched H-2^b skin allograft, which was monitored for rejection for 100 days posttransplant. B, Graft survival graph (2 independent assays) of 3 groups of mice receiving wildtype (WT) Teffs only (n = 8, black), WT Teffs + control Tregs (n = 11, blue), and WT Teffs + IL-33-Tregs (n = 11, red). Survival data were analyzed using log-rank test (P > .05 considered significant) [Color figure can be viewed at wileyonlinelibrary.com]